We transform discoveries in the gut–brain axis, advanced microbiology and nanotechnology into clinically validated, scalable platforms for neurological health, precision nutrition, dermocosmetics and human performance.
Our multidisciplinary model connects microbiology, neuroscience, integrative medicine, biotechnology, nanotechnology and clinical operations to convert complex research into protected, reproducible and commercially viable healthcare solutions.
Each platform is designed to move from discovery to validation and industrial scale without losing scientific rigor.
Functional strain isolation, genomic identification, microbiological characterization, scalable fermentation and advanced microencapsulation for gut–brain axis applications.
Bio-intelligent delivery systems engineered to improve stability, protection, absorption and targeted release of microorganisms and bioactive compounds.
High-performance formulations combining biotechnology and multi-phase release for metabolic, gastrointestinal, cognitive and physical performance applications.
Natural bioactives, biotechnology and intelligent delivery for precision skincare, melasma, lifting, lipedema and inside-out beauty programs.
Our CRO and R&D infrastructure operate under Good Clinical Practice principles, integrating clinical validation, regulatory strategy, intellectual property and go-to-market execution.
Through our CRO structure, we mobilize a multidisciplinary network of experienced researchers across protocol development, clinical operations, data quality, safety, regulatory documentation and scientific publication.
A controlled development sequence ensures identity, purity, functionality, stability and scalability.
Natural and controlled biological sources.
Phenotypic and metabolic screening.
Sequencing and international deposit.
Viability and contaminant control.
Adherence, metabolites and bioactivity.
Pilot and industrial fermentation.
Reproducible quality specifications.
Accelerated and real-time stability, strain viability, microencapsulation integrity and targeted release.
Pathogen absence, total counts, endotoxin testing, molecular strain identification and qPCR.
Residual moisture, pH, solubility, dispersion, particle size, uniformity and thermal behavior.
Simulated GI transit, epithelial adhesion, post-release metabolism, cytotoxicity, genotoxicity and sensitization.
Products are the visible layer of deeper proprietary platforms.
The first probiotic with nanotechnology developed specifically for autistic children and supported by robust scientific validation.
Published in BMC Pediatrics, a Springer Nature journal, in March 2026.
Published in Life Sciences by MDPI in May 2026.
Purpose-built biotechnology for autistic children, backed by reproducible scientific evidence.
SCIENTIFICALLY VALIDATEDBiotech NeuroProb is a U.S.-based biotechnology company focused on research, development, clinical validation and commercialization of advanced health technologies. Our planned Arlington, Texas facility will connect scientific excellence with scalable industrial execution and strategic partnerships.
Already operating in the United States: Biotech NeuroProb maintains an active business office in Miami, Florida, supporting corporate operations, strategic development and international partnerships.
Scientific collaborations, licensing, co-development, clinical validation and strategic investment.
contact@biotechneuroprob.com ↗